apatinib + dalpiciclib + endocrine therapy

This combination therapy consists of apatinib, a selective vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase inhibitor, dalpiciclib (SHR6390), a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, and endocrine therapy (such as aromatase inhibitors or fulvestrant). Developed in collaboration with Fudan University and Jiangsu Hengrui Pharmaceuticals, this regimen is being evaluated as a first-line treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, specifically the SNF4 molecular subtype. The SNF4 subtype is characterized by high expression of angiogenesis-related genes, providing a rationale for adding the anti-angiogenic agent apatinib to the standard-of-care CDK4/6 inhibitor and endocrine therapy backbone to improve clinical outcomes and overcome resistance.

Brand names

AitanDalpicix

Other names

Apatinib plus dalpiciclib plus endocrine therapyApatinib plus SHR6390 plus endocrine therapyApatinib combined with CDK4/6i and endocrine therapy